Journal article
Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes
Cardiovascular drugs and therapy, Vol.24(1), pp.61-70
02/01/2010
DOI: 10.1007/s10557-009-6212-5
PMID: 20033270
Abstract
The combination of aspirin and clopidogrel is the mainstay antiplatelet therapy for acute coronary syndromes (ACS). However, the dosing of aspirin, the dosing of clopidogrel, the timing of clopidogrel initiation as well as the duration of clopidogrel therapy remain controversial matters. Clopidogrel resistance is an emerging concept with potential clinical implications. In the era of clopidogrel and bivalirudin, the role of glycoprotein IIb/IIIa antagonists is being challenged, yet they are still indicated in a select high-risk population. Concerning anticoagulant use in ACS, newer agents, bivalirudin and fondaparinux, have improved outcomes in comparison to heparin in patients managed with an invasive or conservative strategy, respectively. Combining multiple antiplatelet agents and an anticoagulant is the standard of care for ACS.
Details
- Title: Subtitle
- Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes
- Creators
- Elias B. Hanna - University of OklahomaDavid Luke Glancy - Louisiana State UniversityJorge F. Saucedo - University of Oklahoma
- Resource Type
- Journal article
- Publication Details
- Cardiovascular drugs and therapy, Vol.24(1), pp.61-70
- Publisher
- Springer Nature
- DOI
- 10.1007/s10557-009-6212-5
- PMID
- 20033270
- ISSN
- 0920-3206
- eISSN
- 1573-7241
- Number of pages
- 10
- Language
- English
- Date published
- 02/01/2010
- Academic Unit
- Cardiovascular Medicine; Internal Medicine
- Record Identifier
- 9984359850602771
Metrics
24 Record Views